VRTX Stock Forecast 2025-2026
Distance to VRTX Price Targets
VRTX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Vertex (VRTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VRTX and similar high-potential opportunities.
Latest VRTX Stock Price Targets & Analyst Predictions
Based on our analysis of 42 Wall Street analysts, VRTX has a bullish consensus with a median price target of $515.16 (ranging from $330.00 to $615.00). The overall analyst rating is Buy (7.9/10). Currently trading at $502.55, the median forecast implies a 2.5% upside. This outlook is supported by 20 Buy, 12 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRTX Analyst Ratings
VRTX Price Target Range
Latest VRTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 20, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $408.00 |
| Feb 12, 2025 | Canaccord Genuity | Whitney Ijem | Hold | Upgrade | $424.00 |
| Feb 11, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Feb 11, 2025 | Scotiabank | Greg Harrison | Sector Perform | Maintains | $450.00 |
| Feb 11, 2025 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $480.00 |
| Feb 11, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $520.00 |
| Feb 11, 2025 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $459.00 |
| Feb 11, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $467.00 |
| Feb 11, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $407.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $550.00 |
| Jan 31, 2025 | Scotiabank | Greg Harrison | Sector Perform | Maintains | $433.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $550.00 |
| Jan 31, 2025 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $480.00 |
| Jan 31, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Jan 30, 2025 | Wells Fargo | Mohit Bansal | Equal-Weight | Downgrade | $460.00 |
| Jan 27, 2025 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $533.00 |
| Jan 24, 2025 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $480.00 |
| Jan 10, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $460.00 |
| Dec 23, 2024 | Scotiabank | Sector Perform | Maintains | $0.00 | |
| Dec 23, 2024 | JP Morgan | Overweight | Maintains | $0.00 |
Vertex Pharmaceuticals Inc. (VRTX) Competitors
The following stocks are similar to Vertex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vertex Pharmaceuticals Inc. (VRTX) Financial Data
Vertex Pharmaceuticals Inc. has a market capitalization of $128.47B with a P/E ratio of 32.8x. The company generates $11.02B in trailing twelve-month revenue with a -4.9% profit margin.
Revenue growth is +15.7% quarter-over-quarter, while maintaining an operating margin of +45.0% and return on equity of -3.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Vertex Pharmaceuticals Inc. (VRTX) Business Model
About Vertex Pharmaceuticals Inc.
Develops innovative therapies for serious diseases.
Vertex Pharmaceuticals generates revenue primarily through the commercialization of its cystic fibrosis therapies. By addressing significant unmet medical needs, the company enhances patient outcomes and leverages its research pipeline to explore treatments for other serious conditions, thereby diversifying its income streams.
Based in Boston, Vertex collaborates with industry players and academic institutions to advance scientific research. Its commitment to innovation positions it as a key player in the biotechnology sector, with a focus on improving patient quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
6,100
CEO
Dr. Reshma Kewalramani FASN, M.D.
Country
United States
IPO Year
1991
Website
www.vrtx.comVertex Pharmaceuticals Inc. (VRTX) Latest News & Analysis
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
13 hours agoVertex Pharmaceuticals (VRTX) closed at $502.55, up 0.45% from the previous trading day.
Vertex Pharmaceuticals' slight increase in stock price indicates market confidence, which could attract investor interest and influence future trading activity.
Final Trades: Vertex Pharma, Netflix and the IYF
15 hours agoThe Investment Committee has released a list of stocks to monitor for the second half of the year.
Highlighting stocks to watch signals potential investment opportunities, indicating trends or companies with growth prospects, which could impact portfolio strategies and market movements.
Proposed tariffs by President Trump on pharmaceutical products made outside the U.S. could disrupt the biopharmaceutical industry, particularly affecting operations in Ireland.
Proposed tariffs on foreign biopharmaceutical products could increase costs for companies reliant on overseas manufacturing, impacting profitability and stock prices in the sector.
Biopharmaceutical stocks are gaining attention as President Trump targets Ireland's pharma status with new tariffs. Jefferies analysts suggest strategic investment opportunities in the sector.
New tariffs targeting Ireland could impact biopharmaceutical companies' profitability, influencing stock performance. Analysts suggest strategies to capitalize on potential sector volatility.
Steve Weiss of Short Hills Capital Partners is purchasing shares in a pharmaceutical company, as discussed on CNBC's "Halftime Report."
Weiss's purchase of the pharmaceutical company signals confidence in its potential, potentially influencing market sentiment and stock performance in that sector.
Biotech stocks are showing breakouts in a volatile market, with Vertex stock highlighted as a key investment opportunity.
Biotech sector strength indicates potential growth opportunities, while Vertex's prominence suggests it could lead gains, attracting investor interest amid market uncertainty.
Frequently Asked Questions About VRTX Stock
What is Vertex Pharmaceuticals Inc.'s (VRTX) stock forecast for 2025?
Based on our analysis of 42 Wall Street analysts, Vertex Pharmaceuticals Inc. (VRTX) has a median price target of $515.16. The highest price target is $615.00 and the lowest is $330.00.
Is VRTX stock a good investment in 2025?
According to current analyst ratings, VRTX has 20 Buy ratings, 12 Hold ratings, and 2 Sell ratings. The stock is currently trading at $502.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRTX stock?
Wall Street analysts predict VRTX stock could reach $515.16 in the next 12 months. This represents a 2.5% increase from the current price of $502.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vertex Pharmaceuticals Inc.'s business model?
Vertex Pharmaceuticals generates revenue primarily through the commercialization of its cystic fibrosis therapies. By addressing significant unmet medical needs, the company enhances patient outcomes and leverages its research pipeline to explore treatments for other serious conditions, thereby diversifying its income streams.
What is the highest forecasted price for VRTX Vertex Pharmaceuticals Inc.?
The highest price target for VRTX is $615.00 from at , which represents a 22.4% increase from the current price of $502.55.
What is the lowest forecasted price for VRTX Vertex Pharmaceuticals Inc.?
Price targets from Wall Street analysts for VRTX are not currently available. The stock is trading at $502.55.
What is the overall VRTX consensus from analysts for Vertex Pharmaceuticals Inc.?
The overall analyst consensus for VRTX is bullish. Out of 42 Wall Street analysts, 20 rate it as Buy, 12 as Hold, and 2 as Sell, with a median price target of $515.16.
How accurate are VRTX stock price projections?
Stock price projections, including those for Vertex Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
